Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 5
2004 7
2005 9
2006 8
2007 9
2008 6
2009 13
2010 11
2011 21
2012 23
2013 20
2014 31
2015 16
2016 22
2017 31
2018 24
2019 25
2020 44
2021 47
2022 60
2023 82
2024 29

Text availability

Article attribute

Article type

Publication date

Search Results

476 results

Results by year

Filters applied: . Clear all
Page 1
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.
Segal-Maurer S, DeJesus E, Stellbrink HJ, Castagna A, Richmond GJ, Sinclair GI, Siripassorn K, Ruane PJ, Berhe M, Wang H, Margot NA, Dvory-Sobol H, Hyland RH, Brainard DM, Rhee MS, Baeten JM, Molina JM; CAPELLA Study Investigators. Segal-Maurer S, et al. Among authors: castagna a. N Engl J Med. 2022 May 12;386(19):1793-1803. doi: 10.1056/NEJMoa2115542. N Engl J Med. 2022. PMID: 35544387 Clinical Trial.
Reply.
Bottanelli M, Ceccarelli D, Galli L, Castagna A, Muccini C. Bottanelli M, et al. Among authors: castagna a. J Infect Dis. 2022 Jun 1;225(11):2050-2051. doi: 10.1093/infdis/jiac070. J Infect Dis. 2022. PMID: 35218659 No abstract available.
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Ramgopal MN, Castagna A, Cazanave C, Diaz-Brito V, Dretler R, Oka S, Osiyemi O, Walmsley S, Sims J, Di Perri G, Sutton K, Sutherland-Phillips D, Berni A, Latham CL, Zhang F, D'Amico R, Pascual Bernáldez M, Van Solingen-Ristea R, Van Eygen V, Patel P, Chounta V, Spreen WR, Garges HP, Smith K, van Wyk J. Ramgopal MN, et al. Among authors: castagna a. Lancet HIV. 2023 Sep;10(9):e566-e577. doi: 10.1016/S2352-3018(23)00136-4. Epub 2023 Aug 8. Lancet HIV. 2023. PMID: 37567205 Clinical Trial.
Bictegravir.
Spagnuolo V, Castagna A, Lazzarin A. Spagnuolo V, et al. Among authors: castagna a. Curr Opin HIV AIDS. 2018 Jul;13(4):326-333. doi: 10.1097/COH.0000000000000468. Curr Opin HIV AIDS. 2018. PMID: 29746268 Review.
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, Ogbuagu O, Malhotra P, Mullane KM, Castagna A, Chai LYA, Roestenberg M, Tsang OTY, Bernasconi E, Le Turnier P, Chang SC, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wang H, Gaggar A, Brainard DM, McPhail MJ, Bhagani S, Ahn MY, Sanyal AJ, Huhn G, Marty FM; GS-US-540-5774 Investigators. Spinner CD, et al. Among authors: castagna a. JAMA. 2020 Sep 15;324(11):1048-1057. doi: 10.1001/jama.2020.16349. JAMA. 2020. PMID: 32821939 Free PMC article. Clinical Trial.
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial.
Ogbuagu O, Segal-Maurer S, Ratanasuwan W, Avihingsanon A, Brinson C, Workowski K, Antinori A, Yazdanpanah Y, Trottier B, Wang H, Margot N, Dvory-Sobol H, Rhee MS, Baeten JM, Molina JM; GS-US-200-4625 investigators. Ogbuagu O, et al. Lancet HIV. 2023 Aug;10(8):e497-e505. doi: 10.1016/S2352-3018(23)00113-3. Epub 2023 Jul 11. Lancet HIV. 2023. PMID: 37451297 Clinical Trial.
Pillars of long-term antiretroviral therapy success.
Taramasso L, Andreoni M, Antinori A, Bandera A, Bonfanti P, Bonora S, Borderi M, Castagna A, Cattelan AM, Celesia BM, Cicalini S, Cingolani A, Cossarizza A, D'Arminio Monforte A, D'Ettorre G, Di Biagio A, Di Giambenedetto S, Di Perri G, Esposito V, Focà E, Gervasoni C, Gori A, Gianotti N, Guaraldi G, Gulminetti R, Lo Caputo S, Madeddu G, Maggi P, Marandola G, Marchetti GC, Mastroianni CM, Mussini C, Perno CF, Rizzardini G, Rusconi S, Santoro M, Sarmati L, Zazzi M, Maggiolo F. Taramasso L, et al. Among authors: castagna a. Pharmacol Res. 2023 Oct;196:106898. doi: 10.1016/j.phrs.2023.106898. Epub 2023 Aug 28. Pharmacol Res. 2023. PMID: 37648103 Free article. Review.
Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium.
Neesgaard B, Greenberg L, Miró JM, Grabmeier-Pfistershammer K, Wandeler G, Smith C, De Wit S, Wit F, Pelchen-Matthews A, Mussini C, Castagna A, Pradier C, d'Arminio Monforte A, Vehreschild JJ, Sönnerborg A, Anne AV, Carr A, Bansi-Matharu L, Lundgren JD, Garges H, Rogatto F, Zangerle R, Günthard HF, Rasmussen LD, Necsoi C, van der Valk M, Menozzi M, Muccini C, Peters L, Mocroft A, Ryom L. Neesgaard B, et al. Among authors: castagna a. Lancet HIV. 2022 Jul;9(7):e474-e485. doi: 10.1016/S2352-3018(22)00094-7. Epub 2022 Jun 7. Lancet HIV. 2022. PMID: 35688166
Two individuals with potential monkeypox virus reinfection.
Raccagni AR, Canetti D, Mileto D, Tamburini AM, Candela C, Albarello L, Bracchitta F, Mancon A, Micheli V, Gismondo MR, Castagna A, Nozza S. Raccagni AR, et al. Among authors: castagna a. Lancet Infect Dis. 2023 May;23(5):522-524. doi: 10.1016/S1473-3099(23)00185-8. Epub 2023 Apr 6. Lancet Infect Dis. 2023. PMID: 37031694 Free PMC article. No abstract available.
476 results